Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis
Authors:
- 7 February 2024
- journal article
- research article
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 33 (4) , 107633
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial InfarctionJAMA, 2022
- Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysisEuropean Journal of Internal Medicine, 2021
- Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)JACC, 2019
- Elevated Lipoprotein(a) and Risk of Ischemic StrokeJACC, 2019
- Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical TranslationCurrent Atherosclerosis Reports, 2018
- Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial FibrillationJACC, 2017
- Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT studyInternational Journal of Cardiology, 2017
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated PatientsJAMA, 2016
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or HigherCardiovascular Drugs and Therapy, 2016
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I studyAmerican Heart Journal, 2015